David Saxon, an analyst from Needham, reiterated the Buy rating on Glaukos. The associated price target was raised to $117.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Saxon has given his Buy rating due to a combination of factors including Glaukos’s strong third-quarter performance in 2025, which exceeded market expectations primarily due to the success of their iDose product. The company’s management has also increased their revenue guidance for 2025 and provided projections for 2026 that align closely with market consensus.
Additionally, the upcoming launch of Epioxa in the first quarter of 2026 and the anticipated phase-out of Photrexa are expected to contribute positively to the company’s revenue and earnings. The continued adoption of iDose and the confidence in its clinical data further support the potential for significant financial upside, reinforcing the Buy rating recommendation.